companydata.dkcompanydata.dk

Alveus Therapeutics ApS: Financial statements 2025

CVR: 44689790

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

Alveus Therapeutics ApS (CVR 44689790) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 22,056,673 and a net result of DKK 2,096,582 compared with DKK -5,608,478 the year before. Equity in the 2025 report amounted to DKK 59,681,194. The solvency ratio was 91.6%. The company had 2 employees in the financial year.

Gross Profit
DKK 22,056,673
Profit/Loss
DKK 2,096,582
Equity
DKK 59,681,194
Total Assets
DKK 65,129,049
Employees
2

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025-22.1M2.1M59.7M2
2024--969K-5.6M-5.6M3

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Alveus Therapeutics ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

Registered as owner of Alveus Therapeutics ApSDec 22, 2025

As of December 22, 2025, is registered as an owner of Alveus Therapeutics ApS with an ownership share of 5%.

Erik Voorspoels steps down as director of Alveus Therapeutics ApSNov 15, 2025

As of November 15, 2025, Erik Voorspoels has stepped down as director of Alveus Therapeutics ApS.

Erik Voorspoels joins Alveus Therapeutics ApS as directorSep 22, 2025

As of September 22, 2025, Erik Voorspoels is registered as director of Alveus Therapeutics ApS.

Marie Louise Lindegaard steps down as director of Alveus Therapeutics ApSSep 22, 2025

As of September 22, 2025, Marie Louise Lindegaard has stepped down as director of Alveus Therapeutics ApS.

Alveus Therapeutics ApS publishes interim reportJun 17, 2025

Alveus Therapeutics ApS has published its interim report for the period March 5, 2024 to December 31, 2024.

Rajkumar Kannan joins Alveus Therapeutics ApS as adm. dir.Apr 30, 2025

As of April 30, 2025, Rajkumar Kannan is registered as adm. dir. of Alveus Therapeutics ApS.

Nayan Gregory Parekh steps down as adm. dir. of Alveus Therapeutics ApSApr 30, 2025

As of April 30, 2025, Nayan Gregory Parekh has stepped down as adm. dir. of Alveus Therapeutics ApS.

About Alveus Therapeutics ApS

Alveus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Rajkumar Kannan. The company's owners include Novo Holdings A/S, Alveus Therapeutics Inc. and FPCI BioDiscovery 7. The company has 12 employees (2026). In 2025, the company reported a gross profit of DKK 22,056,673 and a net result of DKK 2,096,582 compared with DKK -5,608,478 the year before. Equity in the 2025 report amounted to DKK 59,681,194.

Source: annual report 2025, Danish Business Authority

Other financial years